TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P 1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic ...
“The completion of enrollment is an exciting milestone. With our current indications, adults with painful diabetic peripheral neuropathy of the feet and postherpetic neuralgia, we have advanced the ...
The Phase III trial AV001 aims to evaluate QUTENZA® in post- surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after ...